CJC-1295 + Ipamorelin: a GHRH + GHRP research-stack guide

CJC-1295 + Ipamorelin. The CJC-1295 (no DAC) + Ipamorelin pairing is the canonical GHRH-analogue + GHRP combination referenced across growth-hormone-secretagogue research literature — two peptides co-lyophilised in a single vial. This guide is a research-reference summary for Australian researchers: what each component does at the receptor level, why they are combined, and how the blend is verified. It makes no muscle, performance, or human-use claim.

Two receptor classes, one research model

The pairing combines a GHRH analogue with a GHRP because the two act on distinct receptors that converge on the same somatotrophic-axis research model. CJC-1295 (no DAC) is a stabilised GHRH(1-29) analogue (Mod GRF 1-29) that engages the GHRH receptor; Ipamorelin is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a). Because the two receptor classes act at different, convergent points, the combination is the standard reference pairing in the literature — researchers reference each peptide’s pharmacology separately and use the combined vial as a methodological convenience.

The research behind each component

Ipamorelin was characterised by Raun and colleagues (European Journal of Endocrinology, 1998) as the first selective growth-hormone secretagogue, acting on the GHS-R1a receptor cloned by Howard and colleagues (Science, 1996). The stabilising D-Ala2 substitution central to the Mod GRF (1-29) / no-DAC GHRH backbone was characterised by Soule and colleagues (The Journal of Clinical Endocrinology & Metabolism, 1994). For the DAC-versus-no-DAC distinction and the standalone GHRH detail, see the CJC-1295 GHRH research guide.

Why the blend — and how it is tested

The co-lyophilised blend reconstitutes both peptides together in one vial rather than across two — a research-methodology convenience for protocols that reference both compounds. Each component is still independently HPLC-content-tested by Janoshik; because it is a multi-peptide vial, the certificate reports the measured content of each component rather than a single combined purity figure — research-honest, not marketing-shorthand. The certificate is published on the product page and in the lab-reports library; nothing is listed without certificates on file. If a protocol needs the peptides separately, the standalone CJC-1295 (no DAC) and Ipamorelin product pages carry the individual compounds.

Reconstitution and handling for research use

The co-lyophilised vial is reconstituted with bacteriostatic water for laboratory handling; the per-peptide content on the certificate of analysis is the canonical reference for the concentration math. Store the lyophilised powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles.

Compliance and research-use framing

The CJC-1295 (no DAC) + Ipamorelin blend is not TGA-approved and is not a therapeutic good. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption. We make no medical, performance, muscle, or human-use claim about the blend or its components; the material above summarises the published growth-hormone-secretagogue literature for reference only. Researchers should consult primary peer-reviewed sources for receptor-binding data and protocol-specific reference values.